Details of the Drug

General Information of Drug (ID: DMUBYFM)

Drug Name
ACE-041
Synonyms
N-(5-bromo-2-methylpyridin-4-yl)acetamide; 1244949-22-1; ACE041; DTXSID10670359; 4605AA; ZINC38540942; AKOS016011880; FCH1349294; AJ-96556; EN001564; KB-258244; AX8247344; Acetamide, N-(5-bromo-2-methyl-4-pyridinyl)-
Indication
Disease Entry ICD 11 Status REF
Age-related macular degeneration 9B75.0 Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 229.07
Logarithm of the Partition Coefficient (xlogp) 1.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C8H9BrN2O
IUPAC Name
N-(5-bromo-2-methylpyridin-4-yl)acetamide
Canonical SMILES
CC1=CC(=C(C=N1)Br)NC(=O)C
InChI
InChI=1S/C8H9BrN2O/c1-5-3-8(11-6(2)12)7(9)4-10-5/h3-4H,1-2H3,(H,10,11,12)
InChIKey
OMGSODSTISOTIL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
45480413
CAS Number
1244949-22-1
TTD ID
D0N9PL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Growth/differentiation factor 2 (GDF2) TTAP4T1 GDF2_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
2 Company report (Acceleron Pharma)